Home › NDC Lookup › RxCUI directory › RxCUI 2589008

3 ML insulin glargine-aglr 100 UNT/ML Pen Injector — RxCUI 2589008

RxNorm drug concept · Semantic clinical drug
RxCUI 2589008 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2589008
Official name3 ML insulin glargine-aglr 100 UNT/ML Pen Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asinsulin glargine-aglr 300 UNT per 3 ML Pen Injector; insulin glargine-aglr 300 UNT in 3 ML Pen Injector
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)32,532 prescriptions · 25 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glargine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Insulin glargine is a long-acting insulin — it's designed to provide a slow, steady background level of insulin over the course of the day, rather than a quick spike like short-act...
  • What exactly is insulin glargine and why did my doctor prescribe it instead of regular insulin?
  • You can take insulin glargine at any time of day that works for your routine — morning, evening, whenever. The key is to take it at the same time every single day. Consistency help...
  • Does it matter what time of day I take my injection?
📖 Read our full Insulin Glargine (rDNA origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin glargine-aglr 100 UNT/ML Pen Inject... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector RxCUI 2589008

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Insulin glargine 274783
    • Insulin glargine-aglr 2589006
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rezvoglar 2589010
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Insulin glargine Pen Injector 1653497
    • Insulin glargine-aglr Pen Injector 2645687
    • Insulin glargine Injectable Product 1157459
    • Insulin glargine-aglr Injectable Product 2660603
    • Insulin glargine Pen Injector [Rezvoglar] 2589013
    • Insulin glargine-aglr Pen Injector [Rezvoglar] 2655626
    • Rezvoglar Injectable Product 2589012
    • Pen Injector 1649571
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Insulin glargine-aglr 100 UNT/ML SCDC · 2589007
  • Insulin glargine Pen Injector SCDF · 1653497
  • Insulin glargine-aglr Pen Injector SCDFP · 2645687
  • Insulin glargine Injectable Product SCDG · 1157459
  • Insulin glargine-aglr Injectable Product SCDGP · 2660603

Brand-Name Concepts

  • 3 ML insulin glargine-aglr 100 UNT/ML Pen Injector [Rezvoglar] SBD · 2589014
  • Insulin glargine-aglr 100 UNT/ML [Rezvoglar] SBDC · 2589011
  • Insulin glargine Pen Injector [Rezvoglar] SBDF · 2589013
  • Insulin glargine-aglr Pen Injector [Rezvoglar] SBDFP · 2655626
  • Rezvoglar Injectable Product SBDG · 2589012
  • Rezvoglar BN · 2589010

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2589008 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00002-8980-05 5 SYRINGE in 1 CARTON (0002-8980-05) / 3 mL in 1 SYRINGE (0... Rezvoglar KwikPen Eli Lilly and Company 2021-12-17
50090-6439-00 5 SYRINGE in 1 CARTON (50090-6439-0) / 3 mL in 1 SYRINGE REZVOGLAR KWIKPEN A-S Medication Solutions 2023-04-17
Observed labelers: A-S Medication Solutions (1) · Eli Lilly and Company (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$5.9195
Range $5.9195–$5.9195 · middle 50% $5.9195–$5.9195 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.